Abstract Fast anterograde and retrograde axoplasmic transports in neurons rely on the activity of molecular motors and are critical for maintenance of neuronal and synaptic functions. Disturbances of axoplasmic transport have been identified in Alzheimer's disease and in animal models of this disease, but their mechanisms are not well understood. In this study we have investigated the distribution and the level of expression of kinesin light chains (KLCs) (responsible for binding of cargos during anterograde transport) and of dynein intermediate chain (DIC) (a component of the dynein complex during retrograde transport) in frontal cortex and cerebellar cortex of control subjects and Alzheimer's disease patients. By immunoblotting, we found a significant decrease in the levels of expression of KLC1 and 2 and DIC in the frontal cortex, but not in the cerebellar cortex, of Alzheimer's disease patients. A significant decrease in the levels of synaptophysin and of tubulin-b3 proteins, two neuronal markers, was also observed. KLC1 and DIC immunoreactivities did not co-localize with neurofibrillary tangles. The mean mRNA levels of KLC1, 2 and DIC were not significantly different between controls and AD patients. In SH-SY5Y neural cells, GSK-3b phosphorylated KLC1, a change associated to decreased association of KLC1 with its cargoes. Increased levels of active GSK-3b and of phosphorylated KLC1 were also observed in AD frontal cortex. We suggest that reduction of KLCs and DIC proteins in AD cortex results from both reduced expression and neuronal loss, and that these reductions and GSK-3b-mediated phosphorylation of KLC1 contribute to disturbances of axoplasmic flows and synaptic integrity in Alzheimer's disease.
Introduction
Accumulations of organelles and various proteins in axons and in cell body of neurons are observed in a number of neurodegenerative diseases [11] . A disruption of axoplasmic transport, an essential mechanism for maintenance of neuronal function is thought to underlie the formation of these lesions in many of these diseases [13, 35] . Axoplasmic transport promotes the transport of proteins or organelles like mitochondria and vesicles along the axon, and occurs along the cytoskeleton tracks, which provides the structural support. The movement of cargos along microtubules requires the action of two main types of molecular motors: kinesins and dyneins that are involved in anterograde and retrograde transport, respectively. Anterograde movement is responsible for traffic of organelles from their site of biogenesis to synapses. On the other hand, retrograde movement allows the return of organelles to the cell body for degradation. Conventional kinesin is composed of two heavy chains (KHC) and two light chains (KLC) [7, 50] . The light chains bind the organelles, whereas the heavy chains contain a binding domain with ATP providing energy for the molecular motor. Cytoplasmic dynein is a complex of two heavy chains (DHC) associated with intermediate chains (DIC) and light chains (DLC). The heavy chains contain the motor domain using ATP hydrolysis. The other chains are involved in binding to vesicular cargo and to dynactin [39] . Phosphorylation of molecular motors represents a regulatory mechanism of axoplasmic transport [21] .
Alzheimer's disease is the most common neurodegenerative disease characterized by progressive cognitive deterioration, and two brain lesions: senile plaques and neurofibrillary tangles. Senile plaque is composed of an extracellular accumulation of Ab peptide surrounded by dystrophic neurites and reactive glial cells. The Ab peptide is generated by cleavage of APP (amyloid precursor protein). Neurofibrillary tangles correspond to intraneuronal inclusions and are composed of abnormally and hyperphosphorylated forms of the microtubule-associated protein tau [8] . Tau proteins stabilize microtubules and their hyperphosphorylation leads to microtubule destabilization [28] , resulting in axoplasmic transports disturbances. Ultrastructural studies in Alzheimer's disease have documented the presence in neurons of accumulations of degraded organelles [18] and of endoplasmic reticulum profiles [43] strongly suggestive of disturbances of axoplasmic transport. Disturbances of axonal transport have also been described in some animal models for AD and tauopathies. Overexpression of mutant APP in transgenic mice caused abnormal transport with axonal swellings [1, 48] . Mutant presenilin 1 reduced axonal transport in mice [40] and oligomeric Ab inhibited fast axonal transport in isolated axoplasm [41] . Transgenic mice overexpressing human wild-type tau [45] or mutant tau [27] also developed axonal swellings suggestive of defects in axonal transport. In vitro motility assays suggested that tau influences the rate of attachment and detachment of motor proteins along microtubules [15, 47] . However, in a mice model overexpressing wild-type tau or in mice deleted for tau, axonal transport rates in retinal ganglion cells were not affected [51] . Also tau binding to microtubules in squid axoplasm did not affect fast axoplasmic transport [34] . In contrast, aggregated filamentous forms of tau inhibited anterograde fast axonal transport in vivo [25] by a mechanism involving activation of GSK-3b [23, 25] .
The mechanisms by which axoplasmic transports are disturbed in AD might thus have several origins, including microtubule dysfunction, altered binding of molecular motors by competition, physical or biochemical disturbances induced by aggregated tau and modification of signaling pathways controlling molecular motors activities. These disturbances might also result from the defects of the level of expression of molecular motors. Many of these mechanisms have been analyzed mainly in experimental in vitro and in vivo systems, and their relevance for axoplasmic transport deficits in AD needs to be further assessed. To further document the abnormalities of axoplasmic flows disturbances in AD, we have investigated in this study the phosphorylation and the level of expression of kinesin light chain (KLCs) and of dynein intermediate chain (DIC) in brain tissue of AD patients.
Materials and methods

Brain tissue
Human brain tissue samples taken at autopsy from five control subjects and eight demented patients clinically diagnosed as Alzheimer's disease were fixed with formalin 10% and embedded in paraffin. Some samples of the frontal cortex and cerebellum were kept at -80°C. The neuropathological examination confirmed the presence of numerous senile plaques and neurofibrillary tangles. Table 1 summarizes the clinical data and the neuropathological staging of control subjects and AD patients according to Braak and Braak [6] stageing for NFT and CERAD plaque score for senile plaques [31] . All AD patients had a Braak's NFT stage V or VI, and a CERAD age-related plaque score C or B (for one patient). All studies on post-mortem brain tissue were performed in compliance and following approval of the Ethical Committee of the Medical School of the Free University of Brussels.
Preparation of tissue and cell homogenates and immunoblotting Human brain samples were homogenized in a RIPA buffer containing Tris 50 mM, pH 7.4, NaCl 150 mM, NP40 1%, deoxycholate-Na 0.25%, PMSF 1 mM, leupeptin 25 lg/ml, pepstatin 25 lg/ml, Na4P2O 7 Á10H 2 O 10 mM, NaF 20 mM and Na 3 VO 4 1 mM. After centrifugation of homogenates (20,000g, 20 min) , the levels of proteins in supernatants were estimated with the Bradford method. SH-SY5Y cells were scrapped and homogenized in a buffer containing proteases and phosphatases inhibitors (Tris 50 mM, EDTA 10 mM, NaCl 100 mM, pH 7.4, PMSF 1 mM, leupeptin 25 lg/ml, pepstatin 25 lg/ml, Na 3 VO 4 1 mM, Na4P2O 7 Á10H 2 O 10 mM, NaF 20 mM). Samples were run on 10% (w/v) sodium dodecyl sulfate polyacrylamide gels and proteins were electrophoretically transferred to nitrocellulose membrane. Membranes were blocked in non-fat milk (10% (w/v) in TBS) and then incubated with the primary antibody. For ECL detection, the secondary antibody was an anti-mouse (Sigma) or an anti-rabbit (Cell Signaling) antibody conjugated to horseradish peroxidase. After secondary antibody incubation, blots were developed using the ECL kit Supersignal west Pico chemiluminescent Substrate (Pierce) and exposed to CL-Xposure film (Pierce).
Antibodies
The B19 rabbit polyclonal antibody is a phosphorylationindependent tau antibody previously described [10] . The mouse monoclonal antibody PHF-1 (kindly provided by Drs. P. Davies, New York) is specific for tau phosphorylated at Ser396/404 [37] . The following antibodies were also used: mouse monoclonal antibodies to DIC (MAB1618, Chemicon), to tubulin-b3 (T8660, Sigma), to a-tubulin (T9026, Sigma, DM1A) to GSK-3b (TPKI, Transduction Laboratories), to phosphoserine (abcam) and rabbit polyclonal antibodies to KLC1 (H-75, Santa Cruz), to KLC2 (abcam), to Ab42 (Biosource) and to actin (A2066, Sigma). The rabbit polyclonal antibody to pY279/ pY216-GSK-3a/b detects the active form of GSK-3 phosphorylated on Tyrosine 279 (GSK-3a) and on Tyrosine 216 (GSK-3b) (Biosource). The anti-synaptophysin antibody is a rabbit monoclonal antibody against the C-terminus end of synaptophysin (clone YE269, Millipore).
Dephosphorylation of brain samples
To check for a possible reduction of affinity of KLC1 antibody to phosphorylated KLC1, homogenates of frontal cortex were dephosphorylated with lambda phosphatase prior to SDS-PAGE and immunoblotting. Samples containing 10 lg of proteins were incubated for 2 h at 30°C with 2,000 U of lambda phosphatase (New England BioLabs) in 50 mM Tris-HCl, 100 mM NaCl, 0.1 mM EGTA, 2 mM dithiothreitol, 2 mM MnCl 2 , 0.1% Brij 35, pH 7.5.
Immunohistochemistry
Tissues samples from the frontal cortex were fixed with 4% paraformaldehyde, cryo preserved in 30% sucrose and embedded in tissue-Tek OCT compound. Cryosections (14 lm of thickness) were blocked in 10% serum with 0.1% Triton X-100 for 1 h. Double-immunofluorescent labeling was performed with the anti-KLC1 and the phosphotau PHF1 antibodies, or the anti-DIC and the B19 tau antibodies. Primary antibodies were diluted in 1% serum with 0.1% Triton X-100 and incubated overnight at room temperature. After washing with 0.1% Triton X-100, cryosections were incubated with a secondary antibody conjugated to biotin (Vector) and a secondary antibody conjugated to Alexa594 (Molecular Probes) for 30 min with the streptavidine-peroxidase complex (diluted in TNB buffer), followed by 10 min incubation with Tyramide-FITC diluted 1/50 in amplification buffer (Perkin Elmer). Sections were washed and mounted using gelvatol medium. Sections were examined on an Axiovert 200 M Zeiss microscope using phase contrast optics and combination of fluorescence filters for FITC and Texas Red. Digital images were acquired using a black and white camera (Zeiss Axiocam MRm) and the Axiovision software (Zeiss) with an ApoTome system (Zeiss). Paraffin sections were immunolabeled using the ABC method as previously described [26] . Briefly, tissue sections, after inhibition of endogenous peroxidase with H 2 O 2 , were sequentially treated with the blocking solution (10% (v/v) normal horse serum in TBS (0.01 M Tris, 0.15 M NaCl, pH 7.4), incubated overnight with the diluted primary antibody, and then with goat antirabbit antibodies conjugated to biotin (Vector) followed by the ABC complex (Vector Laboratories). The peroxidase activity was developed using diaminobenzidine as chromogen. Digital images were acquired using a Zeiss HR Axiocam camera and the Axiovision software on an AxioImagerM1 Zeiss microscope.
Quantification of Ab load
Paraffin sections of frontal cortex from control and AD patients were immunolabeled with the anti-Ab42 antibody (ABC method) after pretreatment of sections with formic acid as described [5] . Black and white digital images of four fields of views (each 669 9 844 lm) randomly distributed along the cortical ribbon were acquired for each case. The Ab immunlabeled area was determined in each image by detecting positive pixels using a constant threshold (manually optimized) with the Image J program, and expressed as a percentage of the total surface of the field of view. The mean value of the four fields of views was determined for each case. Table I) for human actin, kinesin light chain 1 (KLC1), kinesin light chain 2 (KLC2), DIC and hypoxanthine-guanine phosphoribosyltransferase (HPRT) were designed with Primer3 software (White head Institute for Biomedical Research, Cambridge, MA). Gene expression level of each mRNA was calculated in duplicate, and then normalized to actin or HPRT mRNAs levels. Specific amplifications were confirmed by melting curve analysis and migration on agarose gel.
Plasmids vectors
The pcDNA5/FRT GSK-3b-EGFP encodes wild-type GSK-3b and the pcDNA5/FRT GSK-3b-S9A-EGFP encodes an active form of GSK-3b with a Ser to Ala mutation that avoids inactivating phosphorylation at Ser9 [16, 32] . The pcDNA5/FRT GSK-3b-K85A, kindly provided by Dr Doble, encodes a kinase-dead GSK-3b with a Lys to Ala mutation. To generate an EGFP-GSK-3b-K85A fusion protein we used a PCR-based strategy. The pcDNA5/FRT GSK-3b-EGFP was first cleaved by KpnI and ApaI to release the wild-type GSK-3b. Oligonucleotide primers were designed to amplify the sequence encoding for GSK-3b-K85A from the pcDNA5/FRT GSK-3b-K85A and to introduce a KpnI site to its 5 0 end and an ApaI site to its 3 0 end. The KpnI/ApaI-digested PCR products were then ligated into the pcDNA5/FRT downstream the EGFP sequence resulting in the pcDNA/FRT GSK-3b-K85A-EGFP encoding for EGFP-GSK-3b-K85A fusion protein.
The positive recombinant was identified by PCR analysis and restriction endonuclease analysis. The pcDNA3-EGFP plasmid (Clontech) is a cloning vector encoding a variant of wild-type enhanced green fluorescent protein (EGFP). Preparations of stock plasmids solutions were performed using the Nucleobond PC500 kit (Stratagene).
Transfection of SH-SY5Y cells
The SH-SY5Y cells were purchased from the EORTCC collection and were cultured in F12 medium added with 10% v/v fetal bovine serum, 100 IUs penicillin and 100 lg/ml streptomycin. Cells were cultured at a density of 200,000 cells/ml for western blot analysis Cells cultures were maintained at 37°C in presence of 5% CO 2 . Transfection of SH-SY5Y was performed 24 h after the plating using Lipofectamine 2000 reagent (Gibco BRL) with a ratio of 3 lg Lipofectamine/1 lg DNA and they were analyzed by immunocytochemistry or western blotting. SH-SY5Y were transfected with either the EGFP, the GSK3b-EGFP, the GSK-3b-S9A-EGFP or the GSK-3b-K85A-EGFP vectors. Cell death and suffering induced by expression of the transfected proteins was estimated by staining of cells with DAPI (1 lg/ml of culture medium) to visualize nuclear morphology [4] . The proportion of cells with condensed and fragmented chromatin was estimated in the different transfection conditions. Viability of SH-SY5Y cells was also estimated 24 h after transfection with the MTT assay. In some experiments, transfected cells were incubated with the GSK-3b inhibitor SB216763 (Tocris, UK) at a concentration of 10 lm for 6 h before homogenization and immunoprecipitation.
KLC1 immunoprecipitation
The anti-KLC1 antibody (2 lg) was incubated with 50 ll of protein A-Sepharose beads (Sigma) and rotated at 4°C for 1 h. The tissue samples were homogenized in a lysis buffer [HEPES 0.03 M, NaCl 0.03 M, Triton X-100 0.1% (v/v)] and aliquots (100 lg of proteins) were incubated with beads coupled with anti-KLC1 and rotated overnight at 4°C. Controls were performed by incubating samples with protein A-Sepharose beads alone. The beads were then washed three times in lysis buffer and resuspended in an adjusted volume of protein sample buffer. Fractions were then heated at 70°C for 10 min, separated by 10% gradient SDS/PAGE, and transblotted to nitrocellulose membranes for immunodetection with the anti-phosphoserine antibody or the anti-KLC1 antibody. For the antiphosphoserine antibody, the blocking reagent was BSA 10%. For ECL detection, the secondary antibody was an anti-mouse conjugated to biotin (Vector) and Avidin Biotin Complex (Vectastain ABC Kit, Vector).
Statistical analysis
Statistical significance was determined by Student's t test and by one-way Anova (with Bonferroni post-tests) and correlation analysis performed with Spearman's coefficient using Prism 4 software (Graphpad).
Results
Levels of abnormal PHF-tau proteins and of Ab in frontal cortex of controls and AD patients
We checked for the presence of phosphotau proteins with the PHF-1 antibody in control and AD samples of frontal cortex used for assessing the levels of KLC and DIC ( Supplementary Fig. S1 ). As described previously [9] , we observed in the eight AD samples three main PHF-1 positive bands between 50 and 70 kDa corresponding to hyperphosphorylated tau proteins, a smear of higher molecular weight tau species corresponding to aggregated species and lower molecular weight tau degradation products. We observed also a weak PHF-1 immunoreactivity in one control homogenate (Braak Stage II-III). No PHF-1 immunoreactivity was detected in the other samples from control subjects. The mean level of Ab load in the frontal cortex samples (as estimated by quantification of immunolabeled Ab areas) was significantly higher in AD patients when compared with controls (p \ 0.05, by Student t test) (data not shown).
Levels of KLC and of DIC are reduced in AD frontal cortex but not in the cerebellar cortex
We then investigated whether expression levels of KLC and DIC were modified in the same homogenates of the frontal cortex. The anti-KLC1 antibody detected a 61 kDa protein (Fig. 1a) , the expected molecular weight of KLC1, and the anti-DIC antibody detected a single species of 74 kDa (Fig. 1b) , corresponding to the DIC. Although some variations were observed between AD cases, quantification of KLC1 immunoreactivity normalized with actin revealed that the average KLC1 levels in AD reached only 48.76% ± 8.55 (mean ± SEM) of control levels (Fig. 1d) , a difference statistically significant (p = 0.0159, by Student t test). The levels of KLC2 immunoreactivity normalized with actin were also significantly decreased in the frontal cortex of AD patients (67.62 ± 5.30, mean ± SEM) (p = 0.0058, by Student t test) (data not shown). Quantification of DIC reactivity normalized with actin showed that the protein levels in AD reached 44.95% ± 10.97 (mean ± SEM) of control levels (Fig. 1e) , a reduction also significantly different (p = 0.0176, by Student t test).
We then investigated whether expression levels of KLC1 and DIC were modified in samples of the cerebellar cortex from the same control and AD cases. Quantification of KLC1 and DIC immunoreactivity normalized with actin revealed that the average KLC1 and DIC levels in cerebellum were similar in AD patients and in control cases (Fig. 1i, j) . Furthermore, the reduction of KLC1 and DIC in the frontal cortex of AD patients was not significantly correlated (Spearman's test) with the post-mortem delays.
We next analyzed the levels of two neuronal proteins, i.e. tubulin-b3 (a neuron specific tubulin isoform) and synaptophysin (a glycoprotein present in the membrane of presynaptic vesicles) in these samples. The antisynaptophysin antibody detected the glycosylated form of synaptophysin at 40 kDa (Fig. 2b) . We observed a decrease in the level of expression of tubulin-b3 (Fig. 2a) , of synaptophysin (Fig. 2b) and of a-tubulin (Fig. 2c) , but not of actin (Fig. 2d) , in AD frontal cortex. The percentage of tubulin-b3 expression levels in AD normalized with actin was decreased to 42.53% ± 9.53 of levels in control subjects (p = 0.0215, by Student t test). For synaptophysin, the percentage of expression levels in AD patients normalized with actin was decreased to 63.55% ± 14.76 of levels in control subjects (p = 0.0328, by Student t test). The levels of tubulin-b3 were not decreased in the cerebellar cortex of AD patients (data not shown). We then estimated the levels of KLC1 and of DIC in control and AD samples by normalizing them with the levels of tubulin-b3 and synaptophysin (Fig. 3) : no significant differences were observed in mean levels between control and AD patients, both in the frontal cortex (Fig. 3) and the cerebellar cortex (data not shown). The reduction of KLC1 and of DIC in the frontal cortex of AD patients was correlated with the reduction of tubulin-b3 (Spearman's test, p = 0.028 and p = 0.048, respectively), but not with the reduction of synaptophysin. The reductions of KLC1 and DIC were highly correlated between them (p \ 0.001).
Reductions of KLC1 and DIC levels are not correlated with loads of Ab or PHF-1 positive tau
We next compared the levels of KLC1 and DIC with the load of Ab or PHF-1 positive tau in the corresponding cases. The levels of KLC1 (p = 0.59) and DIC (p = 0. 13) were not significantly correlated with the levels of PHFpositive tau in the frontal cortex of AD cases (Spearman's test). The levels of KLC1 (p = 0.55) and DIC (p = 0.33) were also not significantly correlated with the levels of Ab in the frontal cortex of AD cases or when including control cases in this analysis.
Levels of KLC and DIC mRNAs in control and AD frontal cortex
We next analyzed by quantitative PCR the levels of KLC1, DIC, and KLC2 in samples of the frontal cortex of control subjects and AD patients (Fig. 4) . The mean levels of KLC1 and DIC mRNAs normalized to actin mRNAs tend to be lower in AD patients, although not significantly. These mean levels were similar between controls and AD patients when normalized to HPRT mRNAs. The mean levels of KLC2 mRNAs were also similar between controls and AD patients. 
KLC1 immunoreactivities are decreased in AD and do not co-localize with NFT in AD brain
We performed then an immunolabeling with the anti-KLC1 antibody on paraffin tissue sections of the frontal cortex in control and AD cases. Neurons in the frontal cortex showed a granular and vesicular-like KLC1 immunoreactivity in cell bodies and dendrites (Fig. 5a ). This vesicular immunoreactivity was decreased in most AD cases (Fig. 5b) . Since a binding between kinesin and tau has been reported [12] , we assessed the relationship between tau and KLC1 or DIC immunoreactivities in tangles-bearing neurons by performing a double immunolabeling with the anti-tau and the anti-KLC1 or the anti-DIC antibodies on cryostat sections (Fig. 6 ). A few KLC1 or DIC vesicular-like structures were occasionally observed in tangle-bearing neurons but tangles themselves were not or weakly KLC1 or DIC positive.
GSK-3b phosphorylates KLC1 in a cellular model
Since GSK-3b has been reported to phosphorylate KLC in squid axoplasm and KLCs from rat brain in vitro [33] , we studied the ability of GSK-3b to phosphorylate KLC1 in human SH-SY5Y neuroblastoma cells. SH-SY5Y cells were transfected with GSK-3b-EGFP, GSK-3b-S9A-EGFP, GSK-3b-K85A-EGFP or EGFP alone as a control. The expression of GSK-3b-EGFP, GSK-3b-S9A-EGFP, GSK-3b-K85A-EGFP was detected by immunoblotting with an antibody to total GSK-3b (Fig. 7a) . The endogenous GSK-3b was detected in transfected cells at a lower molecular weight (47 kDa) than the GSK-3b conjugated to EGFP (75 kDa). The percentage of cells with a nuclear fragmentation was not significantly different between transfection conditions (data not shown). MTT assays also did not show difference in the percentage of viable cells between the different transfection conditions (data not shown). The enzymatic activity of transfected GSK-3b was assessed by studying changes in phosphorylation of tau, a substrate of GSK-3b, with the PHF-1 phosphotau antibody. An increase of tau phosphorylation was observed in cells transfected with GSK-3b-EGFP or an active form of GSK3b (GSK-3b-S9A-EGFP) (1.99 and 1.49, respectively, after normalization with total tau and by comparison with cells transfected with EGFP alone) (Fig. 7b) . We then immunoprecipitated KLC1 from cells transfected with EGFP, GSK-3b-EGFP, GSK-3b-S9A-EGFP or GSK-3b-K85A-EGFP (Fig. 7c) , and tested the phosphorylation state of immunoprecipitated KLC1 with an antiphosphoserine antibody. The phosphorylation state of KLC1, normalized to total KLC1, was significantly higher in cells expressing GSK-3b-EGFP or GSK-3b-S9A-EGFP but not in cells expressing GSK-3b-K85A-EGFP or EGFP (Fig. 7c3) . KLC1 was not detected when samples were incubated with protein A-Sepharose beads alone. We next 75 kD Anti-GSK-3 (TPK-1)
IP:KLC1 WB:pSerine analyzed phosphorylation levels of immunoprecipitated KLC1 in transfected SH-SY5Y cells treated with the GSK3b inhibitor SB216763. Inhibition of GSK-3b led to a decrease of KLC1 phosphorylation when compared with untreated cells (Fig. 7d) . KLC1 immunoprecipitation was not affected by GSK-3b inhibition, indicating that the anti-KLC1 antibody was not phosphosensitive. Inhibition of GSK-3b was also effective in decreasing tau phosphorylation (assessed with the PHF-1 phosphotau antibody) in transfected cells (data not shown).
Phosphorylation of KLC1 is increased in AD frontal cortex
The active form of GSK-3b is increased in AD brain [26] and we confirmed this observation in the human brain homogenates of the frontal cortex used in the present study ( Fig. 8a-c) . To assess the status of phosphorylation of KLC1 in human homogenates of frontal cortex in control and AD cases, KLC1 was immunoprecipitated with the anti-KLC1 antibody and its phosphorylation state estimated with the anti-phosphoserine antibody, after normalization to total KLC1. An increased phosphorylation of KLC1 was observed in the frontal cortex of AD patients ( Fig. 8d-f ). Since increased phosphorylation of KLC1 might reduce affinity of the anti-KLC1 antibody, we checked if dephosphorylation of brain samples did reduce the level of labeling by the KLC1 antibody by Western blotting. Prior dephosphorylation did not modify the labeling of KLC1 by the KLC1 antibody in homogenates of the frontal cortex of controls and AD subjects (Supplementary Fig. S2 ), another indication that the anti-KLC1 antibody was not phosphosensitive.
Discussion
In this study, we examined the level of expression of the KLCs and of the DIC in the frontal cortex and cerebellum of control subjects and AD patients. The light chain of kinesin is responsible for binding of cargo during anterograde transport. The intermediate chain of dynein is a component of the dynein complex for retrograde transport. By immunoblotting, a significant reduction in mean levels of KLCs and DIC was observed in the frontal cortex of patients with Alzheimer's disease when compared with control subjects, i.e. in a brain area affected in the disease. By immunohistochemistry, we also observed a reduction of KLC1 immunoreactivity in neurons in most AD patients. We also studied the protein expression level of KLC1 and DIC in the cerebellar cortex of the same control subjects and Alzheimer patients, a brain area spared in the disease. We did not detect change in the levels of KLC1 and DIC in homogenates of cerebellum of AD patients, indicating that the reduction of KLC1 and DIC was specific for an affected area, the frontal cortex. These reduced levels of KLCs and DIC in AD could play a role in functional abnormalities in the kinesin-and dyneindependent transports, leading to the deficits of axoplasmic transport observed in AD. We did not observe a significant reduction of KLCs and DIC mRNAs in frontal cortex in AD patients, suggesting that reduction of KLC and DIC proteins did not primarily result from reduced transcriptional activity. This reduction of KLCs and DIC proteins could however result from reduced mRNA stability or translational activity in neurons in AD, or from increased protein degradation. Increase of Ab peptides or PHF-tau proteins might be linked to this reduction, but we could not find a significant correlation between KLC1 or DIC reduction and Ab amyloid or PHF-tau proteins levels. However, if low levels of PHF-tau proteins or Ab are sufficient to provoke significant reduction of the cellular levels of KLCs and DIC, the heavy accumulation of PHF-tau in our AD cases, and of Ab, might mask any potential correlation between these measures at least in advanced AD cases.
Alternatively, the reduced levels of KLC1 and DIC observed in the frontal cortex of AD patients could also be linked to neuronal loss. Neuronal loss in several brain regions (especially in areas of association cortex, such as the frontal cortex) has been observed in AD [36] . The levels of tubulin-b3 (a neuron specific tubulin isoform) and of synaptophysin were reduced in the frontal cortex but not in the cerebellum in AD in our samples. The reduction of these two markers in the frontal cortex is consistent with a neuronal and synaptic loss affecting the frontal cortex. KLC1 and DIC levels normalized with the levels of tubulin-b3 and synaptophysin were not significantly different between AD patients and control subjects in the frontal cortex (and cerebellum), an observation compatible with the hypothesis that the decrease of KLC1 and DIC is a reflect of neuronal and synaptic loss. Synaptic loss is however considered as occurring independently from neuronal loss and could even be greater than neuronal loss in AD patients, leading to an underestimation of the reduction and DIC and KLC1 after normalization with synaptophysin. Since the mean mRNAs level of KLC1, a neuronal enriched form of KLC, was not significantly decreased, it also suggests that decrease of KLC1 protein was not simply due to neuronal loss. Finally, it is possible that the reduction of KLC1 and DIC in patients with AD results from a combination of reduced expression or increased degradation of these proteins and of neuronal loss.
Expression of KLC1 variants might also play a role in susceptibility to development of axoplasmic transport defects in AD. There is an alternative splicing of KLC1 which is the basis of binding specificity with the cargo [30] and genetic variability of KLC1 has been suggested to be a risk factor for early onset Alzheimer's disease [2, 14] . A change in the expression of components of the kinesin or dynein complexes might also influence the metabolism of tau and APP. For instance, a higher accumulation of Ab40 and Ab42 was observed in mutant APP transgenic mice (TgAPPsw) crossed with KLC1 wt /KLC1 null mice compared to single TgAPPsw mice [48] . In KLC1 -/-mice, cytoskeletal disorganization and an accumulation of abnormally phosphorylated tau was also observed [19] . In neuroblastoma cells, treatment with a siRNA against DIC induced abnormal localization and accumulation of APP and tau [24] .
We also observed an increased serine phosphorylation of KLC1 in AD frontal cortex. GSK-3b plays a role in the regulation of kinesin-1 dependent fast anterograde transport by phosphorylating KLCs, decreasing thereafter their association with cargoes and transport of the latter [33] . We previously observed that GSK-3b negatively controls the movements of mitochondria by increasing their pausing periods, depending on molecular motors activity [32] . GSK-3b activity is increased in AD [26, 38] and thus this increased activity of GSK-3b could directly impair kinesinbased transport by increasing the phosphorylation level of KLC1 as we observed. Increased GSK-3b activity could result from reduced negative regulation by wnt and insulin signaling [22] , by exposure to Ab [49] and from the action of aggregated tau [25] . Oligomeric Ab was also found to inhibit axonal transport in isolated axoplasm, through casein kinase2 phosphorylation of KLC [41] .
Interestingly, tau can interact with KLC1 and tau phosphorylation by GSK-3b increases its association with kinesin and facilitates its transport, and might potentially induce an aberrant axonal transport of tau [12] . We did not observe significant co-localization of KLC1 and DIC immunoreactivity with tau immunoreactivity in NFT, suggesting that KLC1 and DIC do not interact with the hyperphosphorylated tau protein in NFT, and were not trapped in NFT. NFT are however composed of abnormally phosphorylated and aggregated PHF-tau, possibly less prone to bind to kinesin.
In isolated axoplasm, recombinant tau filaments were reported to inhibit kinesin-dependent anterograde transport through activation of GSK-3b [25] , an effect mediated by exposure of a phosphatase-activating domain in the aminoterminus of abnormally conformed tau, independently of microtubule binding [23] . Our observation of increased KLC1 serine phosphorylation in human samples containing high levels of PHF-tau proteins and increased levels of active GSK-3b is compatible with a mechanism in which abnormally conformed PHF-tau proteins could drive inhibition of kinesin-dependent transport through KLC1 phosphorylation. GSK-3b was previously found to phosphorylate KLC2 [17] . KLC2 is an ubiquitous form of KLC whereas KLC1 is a neuronal enriched form of KLC [42] . Serine phosphorylation of KLC1 was increased in the neuronal SH-SY5Y cells transfected with GSK-3b and its active form (and not with an inactive mutant). Pharmacological inhibition of GSK-3b with SB216763 also led to a decrease of KLC1 phosphorylation. Although the involvement of other kinases is not completely excluded [3] , these results nevertheless consistently suggest that GSK-3b is involved in phosphorylating KLC1 in SH-SY5Y cells.
These deficits in axoplasmic transport in AD might especially affect the transport of synaptic vesicles and the integrity of synapses, dependent of an adequate transport of synaptic vesicles. KLC1 has been detected in the synaptic fraction [42] , suggesting that it contributes effectively to the transport of synaptic vesicles. Several studies have indicated that changes in levels of kinesin and dynein or in their transport abilities lead to a reduction of the transport of synaptic vesicles. For instance, dissociation of KIF5B from tubulin-b3 led to a reduction in transport of mitochondria and of vesicles containing synaptophysin [46] . A model of KIF1B knockout mice showed reduced transport of synaptic vesicles [52] . A reduction of synaptophysin in AD brain has been reported and interpreted as evidence for synaptic loss [20, 29] . We also observed this reduction of synaptophysin in the frontal cortex of AD patients. The reduction of KLCs and DIC in AD and increased serine phosphorylation of KLC1, leading to reduced transport of synaptic vesicles, might thus contribute to the well-documented synaptic loss in AD [29, 44] .
In conclusion, our study indicates that the levels of KLCs and DIC are reduced and serine phosphorylation of KLC1 is increased in AD frontal cortex and we suggest that these phenomenons contribute to the development of deficits of axoplasmic transport in this disease.
